These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38700337)

  • 21. KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae.
    Findlay J; Poirel L; Juhas M; Nordmann P
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0089021. PubMed ID: 34228551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent
    Shi Q; Shen S; Tang C; Ding L; Guo Y; Yang Y; Wu S; Han R; Yin D; Hu F
    Emerg Microbes Infect; 2024 Dec; 13(1):2361007. PubMed ID: 38801099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series.
    van Asten SAV; Boattini M; Kraakman MEM; Bianco G; Iannaccone M; Costa C; Cavallo R; Bernards AT
    J Infect Chemother; 2021 May; 27(5):778-780. PubMed ID: 33558042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies.
    Amadesi S; Amedeo A; Rinaldi M; Palombo M; Giannella M; Gaibani P
    Diagn Microbiol Infect Dis; 2024 Sep; 110(1):116372. PubMed ID: 38875893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.
    Hobson CA; Pierrat G; Tenaillon O; Bonacorsi S; Bercot B; Jaouen E; Jacquier H; Birgy A
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0044722. PubMed ID: 35980232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.
    Venditti C; Butera O; Meledandri M; Balice MP; Cocciolillo GC; Fontana C; D'Arezzo S; De Giuli C; Antonini M; Capone A; Messina F; Nisii C; Di Caro A
    Clin Microbiol Infect; 2021 Jul; 27(7):1040.e1-1040.e6. PubMed ID: 33775814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double
    Hu D; Wang S; Xu M; Zhang J; Luo X; Zhou W; Ma Q; Ma X
    Microbiol Spectr; 2024 Aug; 12(8):e0033124. PubMed ID: 38984824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
    Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
    J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.
    Zhang X; Zeng W; Kong J; Huang Z; Shu H; Tang M; Qian C; Xu C; Zhou T; Ye J
    J Antimicrob Chemother; 2024 Aug; 79(8):1865-1876. PubMed ID: 38842536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of
    Won EJ; Park K; Jeong YS; Kim J; Choi Y; Kim SH; Kim MN; Sung H
    J Korean Med Sci; 2024 Jul; 39(25):e208. PubMed ID: 38952349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
    Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
    Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 36. Detecting KPC-2 and NDM-1 Coexpression in Klebsiella pneumoniae Complex from Human and Animal Hosts in South America.
    Vásquez-Ponce F; Dantas K; Becerra J; Melocco G; Esposito F; Cardoso B; Rodrigues L; Lima K; de Lima AV; Sellera FP; Mattos R; Trevisoli L; Vianello MA; Sincero T; Di Conza J; Vespero E; Gutkind G; Sampaio J; Lincopan N
    Microbiol Spectr; 2022 Oct; 10(5):e0115922. PubMed ID: 35980188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
    Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
    J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.
    Carattoli A; Arcari G; Bibbolino G; Sacco F; Tomolillo D; Di Lella FM; Trancassini M; Faino L; Venditti M; Antonelli G; Raponi G
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0057421. PubMed ID: 34339281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional features of KPC-109, a novel 270-loop KPC-3 mutant mediating resistance to avibactam-based β-lactamase inhibitor combinations and cefiderocol.
    Di Pilato V; Codda G; Niccolai C; Willison E; Wong JLC; Coppo E; Frankel G; Marchese A; Rossolini GM
    Int J Antimicrob Agents; 2024 Jan; 63(1):107030. PubMed ID: 37931849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
    Shields RK; Clancy CJ; Hao B; Chen L; Press EG; Iovine NM; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.